Regeneron
Coverage of Regeneron in the Nexus archive.
- FDA picks Eli Lilly and Regeneron for program to speed up domestic drug factory reviews
The FDA has selected Eli Lilly and Regeneron for its PreCheck program, which aims to expedite domestic drug factory reviews by assessing facilities during construction. The program could save participating companies up to 14 months in review time.
- A new FDA strategy aims to get medicines to the market faster
The FDA has launched a pilot program with Eli Lilly and Regeneron to accelerate the development and approval of U.S. drug manufacturing facilities by engaging companies during design and construction phases. The initiative aims to reduce delays, improve compliance, and strengthen the domestic pharmaceutical supply chain to reduce reliance on overseas production.
- Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly and Regeneron are among the first seven companies selected by the FDA for its PreCheck Pilot Program, an initiative aimed at accelerating the review of new manufacturing facilities. The program was reported by CNBC.
- Regeneron president followed in role model’s footsteps to achieve the American dream — despite English not being his first language
George Yancopoulos co-founded a remarkably successful company and hired his scientific hero. The article highlights his journey toward achieving the American dream despite English not being his first language.
- Ryanair Gains on Narrower Net Loss; Regeneron Melanoma Trial Failure | Stock Movers
Ryanair reports a narrower net loss, while Regeneron's melanoma trial fails. The news impacts stock market movers. Ryanair's financial performance is improving.
- SEE IT: 2-year-old steals show at White House as Trump spotlights 'miracle cure' for deaf boy
President Donald Trump highlighted 2-year-old Travis Smith, who regained hearing after a gene therapy treatment by Regeneron. The FDA granted accelerated approval for Regeneron's Otarmeni, a gene therapy administered surgically, which the company will provide free in the U.S. Trump also noted Regeneron's agreement to offer discounted drug prices.
- SEE IT: 2-year-old steals show at White House as Trump spotlights 'miracle cure' for deaf boy
President Donald Trump highlighted 2-year-old Travis Smith, who regained hearing through Regeneron's Otarmeni gene therapy, during a White House event. The FDA has granted accelerated approval for the treatment, which Regeneron will provide free in the U.S., though administration costs may apply. The therapy involves surgery similar to cochlear implantation.
- FDA approves first gene therapy for genetic hearing loss
The FDA approved a gene-therapy drug developed by Regeneron to treat genetic hearing loss, marking the first such therapy for this condition. This approval represents a significant advancement in medical treatments for hereditary hearing impairments.
- Trump cuts drug price deal with Regeneron
President Trump announced a drug pricing deal with Regeneron, the 17th pharmaceutical company to agree to his 'most favored nation' policy, lowering prices for Medicaid and cash-paying patients. Critics question the impact of the confidential agreements, as discounts may not affect most Americans on private insurance or Medicare.